Startups

Axogen logo

Axogen

axogeninc.comir.axogeninc.com

Axogen is a Nasdaq-listed medical technology company focused on peripheral nerve regeneration and repair. Its products include Avance acellular nerve allograft, Axoguard nerve connectors, protectors and caps, and Avive+ soft tissue matrix. The company received FDA biologics-license approval for Avance in December 2025, including accelerated approval for specified larger sensory gaps and mixed or motor nerve discontinuities. Led by President and CEO Michael Dale, its public directories list 13 executives and eight directors, with Dale serving in both groups. Axogen invested $7 million in Trace Biosciences on July 28, 2026, supporting investigational nerve-specific surgical imaging. It completed the acquisition of BioCircuit Technologies on October 1, 2026, adding the FDA-cleared NerveTape sutureless nerve-repair device. The announced acquisition agreement specified $200 million cash consideration, subject to customary adjustments, and a spin-out of BioCircuit's electronics research business. Axogen closed a $142.6 million gross public equity offering in January 2026 and priced a separate $208.675 million base public offering in September to fund the acquisition.

Team

Al JacksAl JacksVice President of Quality
Alan M. LevineAlan M. LevineDirector
Amalia De LucaAmalia De LucaVice President of Planning and Business Development
Amy WendellAmy WendellDirector
Craig SwandalCraig SwandalSenior Vice President, Operations
Doris QuackenbushDoris QuackenbushChief Revenue Officer
Erick DeVinneyErick DeVinneyChief Scientific Officer
Ivica DucicIvica DucicChief Medical Officer
Jens Schroeder KempJens Schroeder KempChief Marketing Officer
Jesse BishopJesse BishopVice President of Regulatory
John H. JohnsonJohn H. JohnsonDirector
Joseph (Adrian) TyndallJoseph (Adrian) TyndallDirector
Kathy WeilerKathy WeilerDirector
Lindsey HartleyLindsey HartleyChief Financial Officer
Marc BeganMarc BeganExecutive Vice President and General Counsel
Michael DaleMichael DalePresident, Chief Executive Officer and Board Director
Paul G. ThomasPaul G. ThomasChairman of the Board
Rick DittoRick DittoVP, Global Health Economics, Reimbursement & Policy
Stacy ArnoldStacy ArnoldVice President of Product Development and Research
William BurkeWilliam BurkeDirector

Investments

$200M2026-10-01BioCircuit TechnologiesAxogen
$208M2026-09-10Axogen0 participations
$8M2026-07-29Trace BiosciencesAxogen
$142M2026-01-23Axogen0 participations
$17M2015-08-26AxogenEW Healthcare Partners